Drug
Atiprimod
Atiprimod is a pharmaceutical drug with 5 clinical trials. Historical success rate of 75.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_1
3
60%
Ph phase_2
2
40%
Phase Distribution
3
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(1)
Other(1)
Detailed Status
Completed3
Terminated1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (60.0%)
Phase 22 (40.0%)
Trials by Status
completed360%
terminated120%
unknown120%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_1
Study of Atiprimod Treatment for Patients With Advanced Cancer
NCT00430014
completedphase_2
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma
NCT00663429
completedphase_2
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
NCT00388063
completedphase_1
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma
NCT00086216
unknownphase_1
An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer
NCT00214838
Clinical Trials (5)
Showing 5 of 5 trials
NCT00430014Phase 1
Study of Atiprimod Treatment for Patients With Advanced Cancer
NCT00663429Phase 2
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma
NCT00388063Phase 2
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
NCT00086216Phase 1
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma
NCT00214838Phase 1
An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5